Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment

  • STATUS
    Not Recruiting
  • End date
    Jun 4, 2023
  • participants needed
    500
  • sponsor
    TauRx Therapeutics Ltd
Updated on 26 January 2021
Investigator
Marcus Wischik
Primary Contact
The Roskamp Institute, Inc. (3.7 mi away) Contact
+247 other location
cognitive impairment
positron emission tomography
dementia
mini-mental state examination
alzheimer's disease
mild cognitive impairment
amyloid
amyloidosis
mental state examination
memantine
acetylcholinesterase
acetylcholinesterase inhibitor
cognitive assessment

Summary

The purpose of this study is to determine the safety and efficacy of TRx0237 16 mg/day and 8 mg/day in the treatment of subjects with Alzheimer's Disease compared to placebo. In addition, an open-label, delayed-start phase is included to demonstrate a disease-modifying effect of TRx0237.

Details
Condition Dementia, Alzheimer's Disease
Treatment Placebo, TRx0237 8 mg/day, TRx0237 16 mg/day
Clinical Study IdentifierNCT03446001
SponsorTauRx Therapeutics Ltd
Last Modified on26 January 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note